Xiamen, China, 22 May, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Amgen Inc. to develop Companion Diagnostic (CDx) tests supporting an investigational molecule within Amgen’s oncology portfolio. The CDx tests are based on AmoyDx’s industry-leading PCR platform.
Under the terms of the agreement, AmoyDx will develop and register the AmoyDx® Lung Cancer PCR Panel (11-in-1) in China, to get NMPA approval for an intended use as a companion diagnostic for AMG 510, a novel investigational small molecule designed to specifically and irreversibly inhibit KRASG12C, in subjects with Non-Small Cell Lung Cancer.
“We announce with great excitement this co-development collaboration for the China market” said Li-Mou Zheng, Ph.D., Founder and CEO of AmoyDx. “AmoyDx has a strong pipeline of diagnostic products for precision medicines. Exploiting our test to help guide treatment decisions will address a high unmet medical need from patients. AmoyDx is a trusted partner with the expertise in R&D, Regulatory Affairs and Commercialization for co-development of companion diagnostic.”
About Amoy Diagnostics Co., Ltd.
Amoy Diagnostics Co., Ltd. (SZSE: 300685) is a leading biotech company which pioneered the development and commercialization of cancer diagnostics in China. It is the largest provider of molecular diagnostics products for personalized healthcare in China, as well as a service center for oncology biomarker analysis. AmoyDx has a market-leading portfolio of molecular tests and is the therapy diagnostics partner for several major multinational pharmaceutical companies offering precision therapies for cancer.